# Open Label Study to Assess the Effect of Secukinumab in Moderate to Severe Papulopustular Rosacea

> **NCT03079531** · PHASE1,PHASE2 · COMPLETED · sponsor: **Anne Chang** · enrollment: 24 (actual)

## Conditions studied

- Papulopustular Rosacea

## Interventions

- **DRUG:** Secukinumab

## Key facts

- **NCT ID:** NCT03079531
- **Lead sponsor:** Anne Chang
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-06-21
- **Primary completion:** 2019-01-25
- **Final completion:** 2019-01-25
- **Target enrollment:** 24 (ACTUAL)
- **Last updated:** 2020-02-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03079531

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03079531, "Open Label Study to Assess the Effect of Secukinumab in Moderate to Severe Papulopustular Rosacea". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT03079531. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*